-- The nucleic acid sequence entering into the composition of the biological material of the invention includes:

- at least one therapeutic antibody gene, which is to say a gene coding for a native, unmodified antibody therefore natural, or an antibody fragment, such as Fab or $F(ab)_2$ or ScFv fragments, or an antibody derivative such as a chimerical antibody or antibody or antibody fragment fused to an effector substance such as a toxin or hormone;
- at least one element guaranteeing the expression of the preceding gene; promoter sequences of the transcription placed upstream of the antibody gene and controlling its expression in the cells not naturally producing antibodies.--

At page 12, after the paragraph ending on line 22, please insert the following:

--BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 (panels 1a and 1b) provides the nucleotide sequence and the amino acid sequence of variable portions of the light chain of the Tg10 antibody;

Figure 2 (panels 1a and 1b) provides the nucleotide sequence and the amino acid sequence of variable portions of the heavy chain of the Tg10 antibody;

Figure 3 depicts the cDNA of the light chain and heavy chain of the Tg10 antibody in the pLXPXSN retroviral vector cloned either on both sides of the IRES sequence of the poliovirus to form the PM130 vector, or individually upstream of the IRES sequence to form the PM117 and PM124 vectors.--

Please insert the sequence listing pages 1-4 at the end of the specification.

In the Claims:

Please cancel claims 1, 4, 5, 11, 13, 14, 20, 21 and 31, without prejudice, and insert new claims 32-42 as follows: